CN102603723B - 阿齐沙坦有机胺盐及其制备方法和用途 - Google Patents
阿齐沙坦有机胺盐及其制备方法和用途 Download PDFInfo
- Publication number
- CN102603723B CN102603723B CN201210007052.2A CN201210007052A CN102603723B CN 102603723 B CN102603723 B CN 102603723B CN 201210007052 A CN201210007052 A CN 201210007052A CN 102603723 B CN102603723 B CN 102603723B
- Authority
- CN
- China
- Prior art keywords
- azilsartan
- organic amine
- choline
- amine salt
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
测试样品 | 引湿性 | 结论(有无引湿性) |
实施例一化合物 | 10.51% | 有 |
实施例二化合物 | 0.02% | 无 |
实施例三化合物 | 5.66% | 有 |
实施例四化合物 | 0.08 | 无 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210007052.2A CN102603723B (zh) | 2011-01-20 | 2012-01-11 | 阿齐沙坦有机胺盐及其制备方法和用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110022311 | 2011-01-20 | ||
CN201110022311.4 | 2011-01-20 | ||
CN201210007052.2A CN102603723B (zh) | 2011-01-20 | 2012-01-11 | 阿齐沙坦有机胺盐及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102603723A CN102603723A (zh) | 2012-07-25 |
CN102603723B true CN102603723B (zh) | 2014-10-08 |
Family
ID=46515148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210007052.2A Active CN102603723B (zh) | 2011-01-20 | 2012-01-11 | 阿齐沙坦有机胺盐及其制备方法和用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9233954B2 (zh) |
EP (1) | EP2666773B1 (zh) |
JP (1) | JP5981940B2 (zh) |
CN (1) | CN102603723B (zh) |
AU (1) | AU2012208863B2 (zh) |
BR (1) | BR112013017982A2 (zh) |
CA (1) | CA2824316C (zh) |
HK (1) | HK1169826A1 (zh) |
MX (1) | MX340590B (zh) |
RU (1) | RU2600986C2 (zh) |
TW (1) | TWI519531B (zh) |
WO (1) | WO2012097697A1 (zh) |
ZA (1) | ZA201305059B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103113364B (zh) * | 2012-08-27 | 2015-11-18 | 南京华威医药科技开发有限公司 | 阿齐沙坦多晶型的制备方法 |
CN103601723B (zh) * | 2013-11-19 | 2016-04-27 | 合肥远志医药科技开发有限公司 | 一种阿齐沙坦的工业化生产方法 |
JP2017036215A (ja) * | 2013-12-27 | 2017-02-16 | トーアエイヨー株式会社 | アンジオテンシンii受容体拮抗物質の塩 |
CN105037341B (zh) * | 2014-04-04 | 2019-12-03 | 江苏豪森药业集团有限公司 | 阿齐沙坦醇铵晶型及其制备方法 |
CN105503848A (zh) * | 2014-10-13 | 2016-04-20 | 江苏豪森药业集团有限公司 | 阿齐沙坦有机胺盐复合物及其制备方法和用途 |
CZ2014702A3 (cs) | 2014-10-15 | 2016-04-27 | Zentiva, K.S. | Způsob přípravy vysoce čistého azilsartanu |
CN108113988A (zh) * | 2016-11-29 | 2018-06-05 | 江苏恒瑞医药股份有限公司 | 一种romk抑制剂与arb联合在制备治疗和/或预防高血压或心力衰竭的药物中的用途 |
CN107286145A (zh) * | 2017-08-14 | 2017-10-24 | 广州奈米微晶生物科技有限公司 | 一种阿齐沙坦哌嗪盐溶剂合物及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1452176A1 (en) * | 2001-12-03 | 2004-09-01 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
WO2006038722A1 (en) * | 2004-10-07 | 2006-04-13 | Takeda Pharmaceutical Company Limited | Agent for prophylaxis or treatment of metabolic syndrome |
CN101921264A (zh) * | 2009-06-15 | 2010-12-22 | 江苏豪森医药集团有限公司 | 坎地沙坦有机胺盐及其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA924666B (en) * | 1991-06-27 | 1993-12-24 | Takeda Chemical Industries Ltd | Heterocyclic compounds, their production and use |
IL102183A (en) * | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
CA2415962C (en) * | 2000-07-19 | 2010-07-06 | Novartis Ag | Valsartan salts |
JP4484427B2 (ja) * | 2001-12-03 | 2010-06-16 | 武田薬品工業株式会社 | インスリン抵抗性改善剤 |
US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
SI22297A (sl) * | 2006-06-23 | 2007-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Priprava soli telmisartana |
CZ2008469A3 (cs) * | 2008-07-31 | 2009-10-29 | Zentiva, A. S. | Telmisartan tablety |
WO2010075347A2 (en) | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
JP2013512199A (ja) * | 2009-11-30 | 2013-04-11 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | アジルサルタン有機アミン塩、その製造方法及び使用 |
-
2012
- 2012-01-11 JP JP2013549704A patent/JP5981940B2/ja not_active Expired - Fee Related
- 2012-01-11 CA CA2824316A patent/CA2824316C/en not_active Expired - Fee Related
- 2012-01-11 AU AU2012208863A patent/AU2012208863B2/en not_active Ceased
- 2012-01-11 EP EP12736637.5A patent/EP2666773B1/en not_active Not-in-force
- 2012-01-11 RU RU2013137223/04A patent/RU2600986C2/ru active
- 2012-01-11 CN CN201210007052.2A patent/CN102603723B/zh active Active
- 2012-01-11 MX MX2013008197A patent/MX340590B/es active IP Right Grant
- 2012-01-11 BR BR112013017982-1A patent/BR112013017982A2/pt not_active Application Discontinuation
- 2012-01-11 US US13/979,931 patent/US9233954B2/en not_active Expired - Fee Related
- 2012-01-11 WO PCT/CN2012/070219 patent/WO2012097697A1/zh active Application Filing
- 2012-01-18 TW TW101101892A patent/TWI519531B/zh not_active IP Right Cessation
- 2012-10-23 HK HK12110538.4A patent/HK1169826A1/zh not_active IP Right Cessation
-
2013
- 2013-07-05 ZA ZA2013/05059A patent/ZA201305059B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1452176A1 (en) * | 2001-12-03 | 2004-09-01 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
WO2006038722A1 (en) * | 2004-10-07 | 2006-04-13 | Takeda Pharmaceutical Company Limited | Agent for prophylaxis or treatment of metabolic syndrome |
CN101921264A (zh) * | 2009-06-15 | 2010-12-22 | 江苏豪森医药集团有限公司 | 坎地沙坦有机胺盐及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
US20130296334A1 (en) | 2013-11-07 |
CN102603723A (zh) | 2012-07-25 |
CA2824316C (en) | 2020-07-07 |
RU2013137223A (ru) | 2015-02-27 |
JP2014502978A (ja) | 2014-02-06 |
AU2012208863A1 (en) | 2013-08-01 |
HK1169826A1 (zh) | 2013-02-08 |
JP5981940B2 (ja) | 2016-08-31 |
EP2666773A1 (en) | 2013-11-27 |
EP2666773A4 (en) | 2014-06-11 |
ZA201305059B (en) | 2015-01-28 |
US9233954B2 (en) | 2016-01-12 |
EP2666773A8 (en) | 2014-02-12 |
RU2600986C2 (ru) | 2016-10-27 |
CA2824316A1 (en) | 2012-07-26 |
BR112013017982A2 (pt) | 2020-10-27 |
MX340590B (es) | 2016-07-13 |
WO2012097697A1 (zh) | 2012-07-26 |
EP2666773B1 (en) | 2017-07-26 |
TW201309684A (zh) | 2013-03-01 |
AU2012208863B2 (en) | 2016-07-28 |
TWI519531B (zh) | 2016-02-01 |
MX2013008197A (es) | 2013-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102603723B (zh) | 阿齐沙坦有机胺盐及其制备方法和用途 | |
BR112014028602B1 (pt) | Formulação líquida não aquosa oralmente biodisponível para administração oral | |
JP2014529621A (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
US20220280645A1 (en) | Pharmaceutical Eutectic Salt Formation | |
CA3019091C (en) | Medicament | |
TW201338772A (zh) | 藥學組合物 | |
CN102362855B (zh) | 一种伊曲康唑异构体口服溶液 | |
WO2022111493A1 (zh) | Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途 | |
CN103356478A (zh) | 一种布洛芬注射液组合物及其制备方法 | |
CN115040482B (zh) | 用于治疗高血压的厄贝沙坦脂质体、制剂及其制备方法 | |
CN101921264A (zh) | 坎地沙坦有机胺盐及其制备方法和用途 | |
CN101993433B (zh) | 奥美沙坦有机胺盐及其制备方法和用途 | |
US20220387336A1 (en) | Nanoparticles for targeted non-surgical spaying and neutering | |
WO2022048614A1 (zh) | 一种含氮的饱和杂环化合物的应用 | |
US20210154193A1 (en) | Pharmaceutical compositions for the treatment of pulmonary hypertension | |
US20190117624A1 (en) | Therapeutic agent for inflammatory bowel diseases | |
CN115721657A (zh) | 一种包含非瑟酮的药物组合物、其制备方法及用途 | |
CA3218550A1 (en) | Dosing regimens | |
JPS6334844B2 (zh) | ||
BR112016010338B1 (pt) | Composição farmacêutica compreendendo um composto de diidrogenfosfato de 2-{[3,5-bis(trifluormetil)fenil]carbamoil}-4-clorofenila e uma ou mais bases de bronsted, kit compreendendo o dito composto e uso dos mesmos para tratar ou controlar edema | |
JPS62145018A (ja) | 抗アレルギ−剤 | |
CN104644643A (zh) | 一种复方氢氯噻嗪晶体化合物缬沙坦药物组合物 | |
CN103463015A (zh) | 咪达那新在制备治疗高血压的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1169826 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: JIANGSU HANSOH MEDICAL RESEARCH INSTITUTE CO., LTD. Effective date: 20140618 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140618 Address after: 222047 Lianyungang Development Zone, Jiangsu Province Applicant after: Jiangsu Hansoh Medical Group Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: Jiangsu Hansoh Medical Group Co.,Ltd. Applicant before: Jiangsu Hansoh Medical Research Institute Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1169826 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160315 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL CO., LTD. Address before: 222047 Lianyungang Development Zone, Jiangsu Province Patentee before: Jiangsu Hansoh Medical Group Co.,Ltd. |